Smaller and more frequent IV iron dosing may result in a significant overall reduction in total iron use, according to a study presented at ASN's Renal Week 2009.

Very large doses of IV iron are associated with decreased long-term survival in patients on hemodialysis, but a new analysis presented at ASN's Renal Week 2009 in San Diego probing this association could not establish a convincing reason for the increased mortality.

Anemia in non-diabetic CKD patients increases their risk of long-term mortality, and this predominantly explained by the association between anemia and degree of renal function, according to a study presented at ASN's Renal Week 2009.

Preemptive replacement of hemodialysis (HD) water treatment components could result in significantly increased hemoglobin levels at lower doses of erythropoiesis-stimulating agents in HD patients, British researchers reported in a study presented at Renal Week 2009.

Dialysis patients who have erythropoietin resistance also suffer from wasting, inflammation, or both, which increases their risk of death, according to researchers in The Netherlands who presented their study at Renal Week 2009.

Serum phosphate within the normal range is a strong predictor of CKD progression, according to Italian researchers who presented a study at ASN's Renal Week 2009.

CKD patients who used lanthanum carbonate to manage hyperphosphatemia had a lower mean tablet burden compared with those who took sevelamer hydrochloride or calcium acetate, according to researchers who presented a study at ASN's Renal Week 2009.

Hemodialysis patients who have residual kidney function have lower serum phosphate levels and use less phosphate binders than those without RKF, according to a study presented at ASN's Renal Week 2009.

Researchers who reviewed data from about 60,000 hemodialysis patients found that 73% of them experienced hyperphosphatemia according to a study presented at ASN's Renal Week 2009.

Patients who undergo in-center nocturnal hemodialysis have improved protein and phosphorus status compared with those treated with in-center conventional hemodialysis, according to a study that was presented at ASN's Renal Week 2009.

Elevated serum parathyroid hormone levels are associated with higher serum uric acid levels in the U.S. adult population, investigators reported at ASN's Renal Week 2009.

Participation in a specialty pharmacy improved control of secondary hyperparathyroidism in hemodialysis patients, researchers reported at ASN's Renal Week 2009.

Cinacalcet therapy is safe and effective for treating persistent hyperparathyroidism after renal transplantation, British researchers reported at ASN's Renal Week 2009. The medication is not associated with allograft dysfunction or significant adverse effects.

Obesity in CKD patients is associated with increased parathyroid hormone levels independent of estimated glomerular filtration rate, according to a study presented at ASN's Renal Week 2009.

Ergocalciferol 50,000 units per week and cholecalciferol 2,000 units per day can both correct 25-hydroxyvitamin D (25-OHD) deficiency within two months, but ergocalciferol recipients may achieve higher 25-OHD levels, according to researchers.

It may be possible to detect acute allograft rejection in kidney transplant patients by urinary proteome analysis, according to a new German study that was presented at ASN's Renal Week 2009.

Among pediatric renal transplant recipients, increased age and having a very high or very low BMI, steroid use at the time of hospital discharge are three independent factors associated with an increased risk of new onset diabetes, according to new data presented at ASN's Renal Week 2009.

An intensified-dosing regimen of enteric-coated mycophenolate sodium in combination with basiliximab and standard doses of cyclosporine may result in a lower rate of rejection without compromising safety and tolerability, according to new data presented at ASN's Renal Week 2009.

Treatment of stable renal transplant recipients with a regimen of high-dose folic acid and vitamins B6 and B12 lowers total homocysteine levels better than a low-dose multivitamin containing no folic acid. However, it does not reduce cardiovascular disease outcomes or total mortality in this patient population, according to a study presented at ASN's Renal Week 2009.

Switching to sirolimus from a calcineurin inhibitor may reduce the high risk of skin cancer after kidney transplantation, according to a new multi-centered trial conducted in Australia, New Zealand and the United States that was presented at ASN's Renal Week 2009.